Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.

Abstract

PURPOSE:

Bone metastasis in breast cancer has been linked to activity of c-Src kinase, one of the extensively explored tyrosine kinases in cell biology. The impact of TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors has just recently been integrated into this conception.

METHODS:

An osteotropic clone of MDA-MB-231 cells simulated a model for bone metastasis of triple-negative breast cancer (TNBC). The effects of Dasatinib, a clinically established inhibitor of Src kinases family and Abl were evaluated in vitro and in vivo. In vivo effects of Dasatinib treatment on the occurrence of skeletal metastases were tested in a xenograft mouse model after intra-cardiac injection of osteotropic MDA-MB-231-cells. Ex vivo analyses of the bone sections confirmed intraosseous growth of metastases and allowed determination of osteoclastic activity.

RESULTS:

Treatment of osteotropic MDA-MB-231 cells with Dasatinib inhibited proliferation rates in vitro. A shift in TRAIL-receptor expression towards an induction of oncogenic TRAIL-R2 was observed. In vivo, 15 of 30 mice received an intra-peritoneal treatment with Dasatinib. These mice showed significantly less skeletal metastases in bioluminescence scans. Moreover, a pronounced increase in bone volume was observed in the treatment group, as detected by µ-Computed Tomography. Dasatinib treatment also led to a greater increase in bone density in tibiae without metastatic affection, which was accompanied by reduced recruitment of osteoclasts.

CONCLUSION:

Our observations support the concept of utilizing Dasatinib in targeting early-stage bone metastatic TNBC and sustaining bone health.

• Authors: Thorsten Heilmann, Anna-Lena Rumpf, Marijke Roscher, Maren Tietgen, Olga Will, Mirko Gerle, Timo Damm, Christoph Borzikowsky, Nicolai Maass, Claus-Christian Glüer, Sanjay Tiwari, Anna Trauzold, Christian Schem
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 301 Issue 6 Pg. 1493-1502 (06 2020) ISSN: 1432-0711 [Electronic] Germany
• PMID: 32170411 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Dasatinib

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Bone Neoplasms (secondary)
• Cell Line, Tumor
• Dasatinib (pharmacology, therapeutic use)
• Disease Models, Animal
• Female
• Heterografts
• Mice
• Triple Negative Breast Neoplasms (pathology)
• Xenograft Model Antitumor Assays